Rinnerthaler, G.; Gampenrieder, S.P.; Hackl, H.; Steiner, M.; Monzo-Fuentes, C.; Melchardt, T.; Magnes, T.; Huemer, F.; Westphal, T.; Hufnagl, C.;
et al. Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. J. Clin. Med. 2020, 9, 1663.
https://doi.org/10.3390/jcm9061663
AMA Style
Rinnerthaler G, Gampenrieder SP, Hackl H, Steiner M, Monzo-Fuentes C, Melchardt T, Magnes T, Huemer F, Westphal T, Hufnagl C,
et al. Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. Journal of Clinical Medicine. 2020; 9(6):1663.
https://doi.org/10.3390/jcm9061663
Chicago/Turabian Style
Rinnerthaler, Gabriel, Simon Peter Gampenrieder, Hubert Hackl, Markus Steiner, Claudia Monzo-Fuentes, Thomas Melchardt, Teresa Magnes, Florian Huemer, Theresa Westphal, Clemens Hufnagl,
and et al. 2020. "Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial" Journal of Clinical Medicine 9, no. 6: 1663.
https://doi.org/10.3390/jcm9061663
APA Style
Rinnerthaler, G., Gampenrieder, S. P., Hackl, H., Steiner, M., Monzo-Fuentes, C., Melchardt, T., Magnes, T., Huemer, F., Westphal, T., Hufnagl, C., Hauser-Kronberger, C., Egle, A., & Greil, R.
(2020). Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. Journal of Clinical Medicine, 9(6), 1663.
https://doi.org/10.3390/jcm9061663
